On December 27th, Abbott’s largest acquisition in history has made a breakthrough. The US Federal Trade Commission (FTC) officially approved Abbott (NYSE: ABT) to complete its proposed $25 billion acquisition of St. Jude Medical Corporation (NYSE: STJ). Earlier this year, the deal was approved by the board of directors of both companies, Abbott will pay in cash and $15.1 billion, and is awaiting approval from the shareholders meeting and regulatory authorities. Now with official approval, the synergy between the two companies will be better realized after the completion of the acquisition. Abbott and St. Jude said the deal would combine St. Jude’s strengths in heart failure treatment devices , cardiac catheters and defibrillators with Abbott’s strengths in coronary intervention and valve repair, and expect In 2020, it will generate $500 million in sales and operating income. However, for Abbott, after obtaining FTC approval, Abbott will divest two medical device businesses for cardiovascular surgery: vascular closures and steerable sheaths to address the concerns of the Federal Trade Commission. The solution is that Abbott will sell these specific cardiovascular assets to Japan's Terumo (TYO:4543) for about $1 billion as a step in completing the transaction. The FTC said that the significance of divesting the business is that maintaining the acquisition will not lead to "significant damage to the competition in these two markets." The agency also reminded Abbott whether it had obtained lesion assessment of ablation catheter assets from Advanced Cardiac Therapeutics. Only St. Jude Medical and another company produce the technology, and the FTC warned that the acquisition of new developers in the field could further eliminate additional competition. Medical Brace,Medical Back Brace,Shoulder Back Brace,Medical Wrist Brace Henan Anbang Medical Supplies Co., Ltd. , https://www.anbangmedical.com